NCT03784378CompletedPhase 1
RXDX-105 for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring a RET Gene Fusion and a Patient With Ovarian Cancer Harboring a BRAF Gene Mutation
Memorial Sloan Kettering Cancer Center1 site in 1 country3 target enrollmentStarted: December 14, 2018Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 3
- Locations
- 1
- Primary Endpoint
- Evaluation during treatment/intervention
Study Overview
Brief Summary
This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •This individual patient protocol includes treatment for 3 patients previously enrolled on IRB #15-270 (phase1/1b clinical trial RXDX-105-01):
Exclusion Criteria
- •Any patients other than those described above are excluded.
Arms & Interventions
Participants previously enrolled on Study of RXDX-105
Experimental
Participants were previously enrolled on Study of RXDX-105
Intervention: RXDX-105 (Drug)
Outcomes
Primary Outcomes
Evaluation during treatment/intervention
Time Frame: Through study completion, up to five years.
Safety assessments will be performed as standard of care and as clinically indicated. This will include monitoring of adverse events, including serious adverse events including CTCAE grading.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
Pentixafor Positron Emission Tomography Scan: A New Imaging Test for Staging in Non-small Cell Lung Canceron-small cell lung cancerCancer - Lung - Non small cellNon-small cell lung cancerACTRN12615001265561Oceanic Molecular Imaging30
Withdrawn
Phase 1
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination ChemotherapyCarcinoma, Non-Small-Cell LungNCT00256841Clinical Oncology Research Associates
Recruiting
Not Applicable
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeNon-small Cell Lung CancerNCT05363319Regeneron Pharmaceuticals500
Completed
Phase 2
LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With ChemotherapyCancer of LungCancer of the LungNon-Small Cell Lung CarcinomaCarcinoma, Non-Small Cell LungLung CancerNCT00328588Astellas Pharma Inc37
Completed
Not Applicable
Supportive treatment in non-small cell lung canceron small cell lung cancerNon small cell lung cancerCancerISRCTN96733516Medical Research Council (MRC) (UK)230